Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The development of a targeted adenoviral vector, which can be delivered systemically, is one of the major challenges facing cancer gene therapy. The virus is readily cleared from the bloodstream, can be neutralised by pre-existing antibodies, and has a permissive cellular tropism. Clinical studies using the ONYX virus have shown limited efficacy, but there are several hurdles to overcome to achieve an effective tumor-specific systemic therapy. In this review, we have summarized the various strategies used to overcome the limitations of adenoviral-mediated gene delivery.

Original publication

DOI

10.1038/sj.cgt.7700541

Type

Journal article

Journal

Cancer Gene Ther

Publication Date

12/2002

Volume

9

Pages

1036 - 1042

Keywords

Adenoviridae, Animals, Clinical Trials as Topic, Genetic Therapy, Genetic Vectors, Humans, Neoplasms, Organ Specificity, Promoter Regions, Genetic, Tissue Distribution, Virus Replication